Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Roche Holding Ltd.    ROG   CH0012032048

ROCHE HOLDING LTD.

(ROG)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Roche : faces UK pricing row over multiple sclerosis drug Ocrevus

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/09/2018 | 07:14pm EDT
Logo of Swiss drugmaker Roche is seen at its headquarters in Basel

LONDON (Reuters) - Roche faces a fresh row over drug pricing in Britain, following a decision by the body responsible for medicine use within the state health service not to approve its drug Ocrevus for treating a highly disabling form of multiple sclerosis (MS).

In June, the National Institute for Health and Care Excellence (NICE) endorsed Ocrevus for relapsing-remitting MS - the most common type of the disease - but it has now rejected it for the rarer and more severe primary-progressive form of MS.

Ocrevus is the only available treatment for primary-progressive MS (PPMS), while there are several drugs for relapsing-remitting MS (RRMS), and Roche UK general manager Richard Erwin said Monday's decision was "devastating news" for patients.

It is not the first time the Swiss drugmaker has clashed with NICE, which determines if drugs are cost-effective enough to be used in the National Health Service (NHS) in England and Wales.

Roche has also battled to get a number of its cancer drugs approved by NICE in the past, prompting Chief Executive Severin Schwan to brand Britain's health system as "stupid" three years ago https://uk.reuters.com/article/us-roche-cancer-britain/roche-ceo-attacks-britains-stupid-cancer-drug-system-idUKKCN0R81J620150908.

In the case of Ocrevus, Roche said it had reached a stalemate because the authorities were not allowed to even consider a confidential discounted price for using the drug in PPMS that was different from the RRMS price.

That is a problem because the evidence showing the benefit of Ocrevus in PPMS is not as compelling as in RRMS, so a lower price would be needed to reach NICE cost-effectiveness thresholds.

The restriction meant NICE had to consider the existing RRMS approved price for the PPMS indication and this was deemed too expensive. In a statement, NICE said the size and duration of the drug's benefits in PPMS were uncertain and it could not be considered an acceptable use of NHS resources.

Worldwide, Ocrevus has proved to be a big commercial success for Roche, with sales topping $1 billion in the first half of 2018, and the company said it hoped an agreement could be reached for its use within the NHS.

"Roche is confident that given the flexibility to offer an indication-specific price, we will be able to offer a price that is deemed cost-effective for PPMS," the company said.

(Reporting by Ben Hirschler; Editing by Mark Potter)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ROCHE HOLDING LTD.
07/18Novartis raises full-year targets, aims to settle U.S. lawsuit
RE
07/18Novartis raises full-year targets, aims to settle U.S. lawsuit
RE
07/16Abbott to hike production of lower-cost glucose monitors as diabetes soars
RE
07/12EUROPE : Swiss stocks keep a lid on European shares as pharma drag lingers
RE
07/11EUROPE : European shares dip on pharma drag as Fed optimism sizzles out
RE
07/09GENENTECH : Presents a Broad Range of Data for Hemlibra (Emicizumab-kxwh) Demons..
BU
07/09Roche presents a broad range of data for Hemlibra demonstrating continued ben..
GL
07/08European shares dip on Deutsche Bank, fading hopes of sharp Fed cut
RE
07/08SPARK THERAPEUTICS : Roche, Spark push back takeover deadline in $4.3 billion de..
RE
07/03GENENTECH : Announces Positive Results for First Global Phase III Study Investig..
BU
More news
Financials (CHF)
Sales 2019 60 696 M
EBIT 2019 22 027 M
Net income 2019 14 090 M
Debt 2019 2 214 M
Yield 2019 3,37%
P/E ratio 2019 16,6x
P/E ratio 2020 16,5x
EV / Sales2019 3,76x
EV / Sales2020 3,66x
Capitalization 226 B
Chart ROCHE HOLDING LTD.
Duration : Period :
Roche Holding Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROCHE HOLDING LTD.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 289,59  CHF
Last Close Price 271,20  CHF
Spread / Highest target 31,3%
Spread / Average Target 6,78%
Spread / Lowest Target -26,3%
EPS Revisions
Managers
NameTitle
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
John Irving Bell Non-Executive Director
Andreas Oeri Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING LTD.11.42%234 924
JOHNSON & JOHNSON2.18%350 653
PFIZER-2.08%239 061
ROCHE HOLDING13.37%234 924
NOVARTIS24.46%217 699
MERCK AND COMPANY8.22%212 897